PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.
| Revenue (Most Recent Fiscal Year) | $806.78M |
| Net Income (Most Recent Fiscal Year) | $-363.30M |
| PE Ratio (Current Year Earnings Estimate) | 6.48 |
| PE Ratio (Trailing 12 Months) | 6.57 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.24 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 37.74% |
| Net Margin (Trailing 12 Months) | 35.65% |
| Return on Equity (Trailing 12 Months) | -106.31% |
| Return on Assets (Trailing 12 Months) | 30.61% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.62 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.57 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 1.79 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-2.60 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.83 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.12 |
| Diluted Earnings per Share (Trailing 12 Months) | $6.97 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 79.44M |
| Free Float | 75.07M |
| Market Capitalization | $3.95B |
| Average Volume (Last 20 Days) | 1.35M |
| Beta (Past 60 Months) | 0.54 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.50% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |